Lilly Advances Cholesterol-Lowering Therapy, Hosts Goldman Sachs Chat June 9
LLY•Eli Lilly will host a June 9 fireside chat at the Goldman Sachs Healthcare Conference with Cardiometabolic Health chief Kenneth Custer at 3:20 p.m. ET and advance a potent cholesterol-lowering therapy toward late-stage evaluation. A Hims insider made Lilly share purchase since 2021 and President Trump increased his Q1 stake.
1. Cholesterol-Lowering Therapy Advancement
Lilly confirmed development of a new, high-potency cholesterol-lowering candidate now progressing toward late-stage evaluation. The therapy aims to deliver significant LDL cholesterol reductions, with detailed efficacy and safety data expected in upcoming clinical readouts.
2. Goldman Sachs Conference Participation
On June 9 at 3:20 p.m. ET, Cardiometabolic Health president Kenneth Custer will appear in a fireside chat during the Goldman Sachs 47th Annual Global Healthcare Conference. A live webcast and 90-day replay will be available on Lilly's investor website.
3. Hims Insider Share Purchase
A senior executive from telehealth firm Hims executed its first Lilly share purchase since 2021, reflecting confidence in Lilly’s expanding obesity and cardiometabolic portfolio. The move follows Hims’ strategic pivot toward weight-loss drug distribution.
4. President Trump's Q1 Stake Increase
Former President Donald Trump added to his Eli Lilly holdings during Q1, marking a noteworthy high-profile investment. The increased position underscores bullish sentiment on Lilly’s diabetes, obesity and cardiometabolic growth prospects.
